Operative Therapie des Ovarialkarzinoms

Die Prognose des Ovarialkarzinoms ist wie bei keinem anderen gynäkologischen Malignom von einer nach State of the Art durchgeführten stadiengerechten Operation und vor allem der Expertise des Operateurs abhängig. Nur durch ein adäquates interdisziplinäres Vorgehen gelingt eine makroskopisch tumorfreie Operation der bei Erstdiagnose meist bereits fortgeschrittenen Stadien. Dies soll im Folgenden dargestellt werden.

Schlüsselwörter

primäre Operation - Frühstadien - Lymphonodektomie - neoadjuvante Chemotherapie - Rezidivchirurgie

• Literatur

• 1 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF). S3-Leitlinie Diagnostik, Therapie und Nachsorge maligner Ovarialtumoren, Langversion 3.0 2019. Im Internet: https://www.awmf.org/leitlinien/detail/ll/032-035OL.html Stand: 20.12.2019
• 2 Soper JT, Johnson P, Johnson V. et al. Comprehensive restaging laparotomy in women with apparent early ovarian carcinoma. Obstet Gynecol 1996; 80: 949-953
• 3 Grabowski JP, Harter P, Buhrmann C. et al. Re-operation outcome in patients referred to a gynecologic oncology center with presumed ovarian cancer FIGO I-IIIA after sub-standard initial surgery. Surg Oncol 2012; 21: 31-35
• 4 Bentivegna E, Fruscio R, Roussin S. et al. Long-term follow-up of patients with an isolated ovarian recurrence after conservative treatment of epithelial ovarian cancer: review of the results of an international multicenter study comprising 545 patients. Fertil Steril 2015; 104: 1319-1324
• 5 Colombo N, Sessa C, du Bois A. et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Ann Oncol 2019; 30: 672-705
• 6 Ditto A, Martinelli F, Bogani G. et al. Long-term safety of fertility sparing surgery in early stage ovarian cancer: comparison to standard radical surgical procedures. Gynecol Oncol 2015; 138: 78-82
• 7 Ghezzi F, Cromi A, Fanfani F. et al. Laparoscopic fertility-sparing surgery for early ovarian epithelial cancer: a multi-institutional experience. Gynecol Oncol 2016; 141: 461-465
• 8 Park HJ, Kim DW, Yim GW. et al. Staging laparoscopy for the management of early-stage ovarian cancer: a metaanalysis. Am J Obstet Gynecol 2013; 209: 58.e1-e8
• 9 Fagotti A, Perelli F, Pedone L. et al. Current recommendations for minimally invasive surgical staging in ovarian cancer. Curr Treat Options Oncol 2016; 17: 3
• 10 Galotta V, Ghezzi F, Vizza E. et al. Laparoscopic staging of apparent early stage ovarian cancer: results of a large, retrospective, multi-institutional series. Gynecol Oncol 2014; 135: 428-434
• 11 Radosa JC, Radosa MP, Schweitzer PA. et al. Report on the survey on current opinions and practice of German Society for Gynecologic Endoscopy (AGE) members regarding the laparoscopic treatment of ovarian malignancies. Arch Gynecol Oncol 2018; 297: 1255-1264
• 12 Ceccaroni M, Roviglione G, Bruni F. et al. Laparoscopy for primary cytoreduction with multivisceral resections in advanced ovarian cancer: prospective validation. “The times they are a-changin”?. Surg Endosc 2018; 32: 2026-2037
• 13 Rutten MJ, van Meurs HS, van de Vrie R. et al. Laparoscopy to predict the result of primary cytoreductive surgery in patients with advanced ovarian cancer: a randomized controlled trial. J Clin Oncol 2017; 35: 613-621
• 14 Bristow RE, Tomacruz RS, Armstrong DK. et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002; 20: 1248-1259
• 15 Du Bois A, Reuss A, Pujade-Lauraine E. et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe dʼInvestigateurs Nationaux pour les Etudes des Cancers de lʼOvaire (GINECO). Cancer 2009; 115: 1234-1244
• 16 Horowitz NS, Miller A, Rungruang B. et al. Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis. J Clin Oncol 2015; 33: 937-944
• 17 Vandecaveye V, Dresen R, de Keyzer F. Novel imaging techniques in gynaecological cancer. Curr Opin Oncol 2017; 29: 335-342
• 18 Fagotti A, Ferrandina G, Fanfani F. et al. A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: a pilot study. Ann Surg Oncol 2006; 13: 1156-1161
• 19 Vergote I, Marquette S, Amant F. et al. Port-site metastases after open laparoscopy: a study in 173 patients with advanced ovarian carcinoma. Int J Gynecol Cancer 2005; 15: 776-779
• 20 Querleu D, Planchamp F, Chiva L. et al. European Society of Gynecologic Oncology (ESGO) Guidelines for Ovarian Cancer Surgery. Int J Gynecol Cancer 2017; 27: 1534-1542
• 21 Mourton SM, Temple LK, Abu-Rustum NR. et al. Morbidity of rectosigmoid resection and primary anastomosis in patients undergoing cytoreductive surgery for advanced epithelial ovarian cancer. Gynecol Oncol 2005; 99: 608-614
• 22 Harter P, Sehouli J, Lorusso D. et al. A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms. N Engl J Med 2019; 380: 822-832
• 23 Vergote I, Tropé CG, Amand F. et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010; 363: 943-953
• 24 Kehoe S, Hook J, Nankivell M. et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet 2015; 386: 249-257
• 25 Fotopoulou C, Sehouli J, Aletti G. et al. Value of neoadjuvant chemotherapy for newly diagnosed advanced ovarian cancer: a European perspective. J Clin Oncol 2017; 35: 587-590
• 26 Möbus V, Wandt H, Frickhofen N. et al. Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT. J Clin Oncol 2007; 25: 4187-4193
• 27 Van Driel WJ, Koole SN, Sikorska K. et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med 2018; 378: 230-240
• 28 Lim MC, Chang SJ, Yoo HJ. et al. Randomized trial of hyperthermic intraperitoneal chemotherapy (HIPEC) in women with primary advanced peritoneal, ovarian and tubal cancer. J Clin Oncol 2017; 35 (15 Suppl): 5520
• 29 Du Bois A, Vergote I, Ferron G. et al. Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: the interim analysis of AGO DESKTOP III/ENGOT ov20. J Clin Oncol 2017; 35 (15 Suppl): 5501
• 30 Coleman RL, Spirtos NM, Enserro D. et al. Secondary surgical cytoreduction for recurrent ovarian cancer. N Engl J Med 2019; 381: 1929-1939